【摘 要】
:
Background and Aims: Fibroblast growth factor (FGF)19 has been implicated in the pathogenesis of murine hepa-tocellular carcinoma. Whether it plays a role in the devel-opment or course of human cholangiocarcinoma remains to be determined. The aim of this
【机 构】
:
Section of Hepatology,Department of Medicine,Rady College of Medicine,University of Manitoba,Winnipe
论文部分内容阅读
Background and Aims: Fibroblast growth factor (FGF)19 has been implicated in the pathogenesis of murine hepa-tocellular carcinoma. Whether it plays a role in the devel-opment or course of human cholangiocarcinoma remains to be determined. The aim of this study was to determine whether prolonged exposure to FGF19 results in the trans-formation of non-malignant human cholangiocytes into cells with malignant features. Methods: Human SV-40 trans-fected non-malignant H69 cholangiocytes were cultured with FGF19 (0-50 ng/mL) for 6 weeks, followed by 6 weeks with medium alone. Cell proliferation, invasion, stem cell surface markers, oncofetoprotein expression, state of dif-ferentiation, epithelial-mesenchymal transition (EMT) and interleukin (IL)-6 expression were documented at various time intervals throughout the 12-week period. Results: FGF19 exposure was associated with significant increases in cell proliferation, de-differentiation, EMT and IL-6 expres-sion. However, each of these effects returned to baseline or control values during the 6-week FGF19 free follow-up period. The remaining cell properties remained unaltered. Conclusions: Six weeks of FGF19 exposure did not result in the acquisition of permanent malignant features in non-malignant, human cholangiocytes.
其他文献
Background and Aims: In the last decade, several sec-ond-line therapies followed by sorafenib in patients with ad-vanced hepatocellular carcinoma (HCC) have been reported. But the outcomes were different from each other. This me-ta-analysis aimed to evalu
Background and Aims: The survival rate of patients with hepatocellular carcinoma is variable. The abnormal expres-sion of RNA-binding proteins (RBPs) is closely related to the occurrence and development of malignant tumors. The pri-mary aim of this study
Background and Aims: The impact of coronavirus dis-ease-2019 (COVID-19) on liver function remains to be fully elucidated. This study was designed to investigate such and determine the clinical significance in determining mortality risk. Methods: A retrosp
Background and Aims: Acute-on-chronic liver failure (ACLF) is acute decompensation of liver function in the setting of chronic liver disease, and characterized by high short-term mortality. In this study, we sought to investi-gate the clinical course of p
Background and Aims: Screening for hepatopulmonary syndrome in cirrhotic patients is limited due to the need to perform contrast enhanced echocardiography (CEE) and arterial blood gas (ABG) analysis. We aimed to develop a simple and quick method to screen
Background and Aims: It is critical but challenging to predict the prognosis of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). This study systematically summarized and evaluated the quality and performance of available clinical predi
Background and Aims: The expression of discoidin do-main receptor 1 (DDR1) is commonly up-regulated and undergoes collagen-induced ectodomain (N-terminal) shed-ding during the progression of liver fibrosis. This study aimed to evaluate the clinical utilit
Background and Aims: Currently, insufficient clinical data are available to address whether low-level viremia (LLV) ob-served during antiviral treatment will adversely affect the clinical outcome or whether treatment strategies should be altered if LLV oc
Background and Aims: The overall survival (OS) of hepa-tocellular carcinoma (HCC) remains dismal. Bioinformatic analysis of transcriptome data could identify patients with poor OS and may facilitate clinical decision. This study aimed to develop a prognos
Background and Aims: Protein phosphatase 2A (PP2A) is associated with many cancers. This study aimed to clarify whether PPP2CA, which encodes the alpha isoform of the catalytic subunit of PP2A, plays a role in hepatocellular carcinoma (HCC) and to identif